Track the 셀트리온 stock price and the full management transaction log of the company, a publicly traded company based in South Korea. Shares are quoted on the KR market, under the authority of DART (FSS). Operating in the Health Care sector, 셀트리온 has published 468 insider filings. Market capitalisation: €44,145.5bn. The latest transaction was reported on 16 July 2026 (Purchase). Among the most active insiders: 셀트리온홀딩스. Every trade is openly available.
461
Insider Decl.
n/a
Thresholds
€17m
189 ops.
Buy Volume
€68m
59 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate 셀트리온 Buy (bullish), based on 23 analysts. Average price target: ₩265,452.
Buys €17m€68m Sells
Fundamental score
Ranked 15,770 of 28,753 companies
49.3
score / 100
Value
33
Quality
65
FCF yld0.7%
Earn yld2.3%
EV/EBITDA31.6x
ROE7.3%
Gross mgn59%
Net mgn25%
Debt/EBITDA2.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Celltrion is a South Korean company focused on the development and manufacturing of biosimilar drugs and innovative therapies. It is listed on the Korea Exchange, XKRX.